1. Current pharmacophore based approaches for the development of new anti-Alzheimer's agents.
- Author
-
Sharma P, Sharma S, Yadav Y, Shukla P, and Sagar R
- Subjects
- Humans, Acetylcholinesterase metabolism, Butyrylcholinesterase metabolism, Molecular Structure, Drug Development, Neuroprotective Agents chemistry, Neuroprotective Agents pharmacology, Neuroprotective Agents chemical synthesis, Animals, Pharmacophore, Alzheimer Disease drug therapy, Alzheimer Disease metabolism, tau Proteins metabolism, tau Proteins antagonists & inhibitors, Amyloid beta-Peptides antagonists & inhibitors, Amyloid beta-Peptides metabolism, Cholinesterase Inhibitors pharmacology, Cholinesterase Inhibitors chemistry, Cholinesterase Inhibitors chemical synthesis, Cholinesterase Inhibitors therapeutic use
- Abstract
Amyloid beta peptide (Aβ) and hyperphosphorylated neuronal tau proteins accumulate in neurofibrillary tangles in Alzheimer's disease (AD), a chronic neurodegenerative illness. Chronic inflammation in the brain, which promotes disease progression, is another feature of the Alzheimer's disease pathogenesis. Approximately 60-70 % of dementia cases are caused by AD. The development of effective therapies for the treatment of AD is urgently needed given the severity of the condition and its rapidly rising prevalence. Cholinesterase inhibitors, beta-amyloid (A-beta), tau inhibitors, and many other medications are currently used as preventive medicine for AD. These medications can temporarily suppress dementia symptoms but cannot halt or reverse the disease's progression. Many international pharmaceutical companies have tried numerous times to develop an amyloid clearing medication based on the amyloid hypothesis, but without success. Therefore, the amyloid theory may not be entirely plausible. This review mainly covers the recent and important reported pharmacophores as the starting point to discuss already known targets like tau, butyrylcholinesterase, amyloid beta, and acetylcholinesterase and covers the literature between years 2019-2024., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF